BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 12187959)

  • 21. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
    Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
    Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of the extracellular matrix glycoproteins in ependymomas--an immunohistochemical study with follow-up analysis.
    Zámecník J; Chánová M; Tichý M; Kodet R
    Neoplasma; 2004; 51(3):214-22. PubMed ID: 15254676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of p53 and KI-67 expression with grade and subtype of ependymoma.
    Manasa LP; Uppin MS; Sundaram C
    Indian J Pathol Microbiol; 2012; 55(3):308-13. PubMed ID: 23032822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression of cell cycle regulatory proteins in oligodendroglial tumors.
    Kamiya M; Nakazato Y
    Clin Neuropathol; 2002; 21(2):52-65. PubMed ID: 12005253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor vessel biology in pediatric intracranial ependymoma.
    Wagemakers M; Sie M; Hoving EW; Molema G; de Bont ES; den Dunnen WF
    J Neurosurg Pediatr; 2010 Apr; 5(4):335-41. PubMed ID: 20367336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical expression of cell cycle/apoptosis regulators and epidermal growth factor receptor in pediatric intracranial ependymomas.
    Alexiou GA; Stefanaki K; Moschovi M; Patereli A; Prodromou N; Karentzou O
    J Child Neurol; 2011 Feb; 26(2):195-8. PubMed ID: 20713981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclooxygenase-2 (cox-2) expression and angiogenesis in intracranial ependymomas.
    Onguru O; Kurt B; Gunhan O; Soylemezoglu F
    Clin Neuropathol; 2006; 25(5):216-20. PubMed ID: 17007443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
    Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic use of D2-40 and annexin-1 in ependymal tumors].
    Wang YF; Piao YS; Lu DH; Chen L; Wang W; Yang H; Wei LF
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):595-8. PubMed ID: 22177242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases.
    Prayson RA
    Am J Clin Pathol; 1998 Nov; 110(5):629-34. PubMed ID: 9802348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
    Maiuri F; Del Basso De Caro M; Siciliano A; Peca C; Vergara P; Mariniello G; Pettinato G
    Clin Neuropathol; 2010; 29(2):109-14. PubMed ID: 20175962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial differentiation and proliferative potential in spinal ependymomas.
    Takeuchi H; Kubota T; Sato K; Llena JF; Hirano A
    J Neurooncol; 2002 May; 58(1):13-9. PubMed ID: 12160136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.
    Ho DM; Hsu CY; Wong TT; Chiang H
    J Neurooncol; 2001 Aug; 54(1):77-85. PubMed ID: 11763426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
    Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
    Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients.
    Shuangshoti S; Rushing EJ; Mena H; Olsen C; Sandberg GD
    Cancer; 2005 Jun; 103(12):2598-605. PubMed ID: 15861411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
    Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
    PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis.
    Kuncova K; Janda A; Kasal P; Zamecnik J
    Pathol Oncol Res; 2009 Dec; 15(4):605-14. PubMed ID: 19301151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic relevance of localization and grading in intracranial ependymomas of childhood.
    Ernestus RI; Schröder R; Stützer H; Klug N
    Childs Nerv Syst; 1996 Sep; 12(9):522-6. PubMed ID: 8906366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them].
    Cui Y; Zhao JZ
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(47):3356-8. PubMed ID: 19257969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes.
    Senetta R; Miracco C; Lanzafame S; Chiusa L; Caltabiano R; Galia A; Stella G; Cassoni P
    Neuro Oncol; 2011 Feb; 13(2):176-83. PubMed ID: 21059755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.